ObjectiveThe effectiveness of sugemalimab vs. placebo in post-chemoradiotherapy patients with locally advanced, unresectable stage III NSCLC has been demonstrated and approved by China National Medica
Rare diseases affect more than 30 million individuals, with the majority facing limited treatment options, elevating the urgency to innovative therapeutic solutions. Addressing these medical challenge
Objective The effectiveness of sugemalimab vs. placebo in post-chemoradiotherapy patients with locally advanced, unresectable stage III NSCLC has been demonstrated and approved by China National Medic
